Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment

ABSTRACT

Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with reduced platelet counts and a unique gain-of-function defect in fibrinolysis due to increased expression and storage of urokinase plasminogen activator (uPA) by megakaryocytes. QPD increases risks for bleeding and its key clinical feature is delayed-onset bleeding, following surgery, dental procedures or trauma, which responds only to treatment with fibrinolytic inhibitors. The genetic cause of the disorder is a tandem duplication mutation of the uPA gene, PLAU, which upregulates uPA expression in megakaryocytes by an unknown mechanism. The increased platelet stores of uPA trigger plasmin-mediated degradation of QPD α-granule proteins. The gain-of-function defect in fibrinolysis is thought to be central to the pathogenesis of QPD bleeding as the activation of QPD platelets leads to release of uPA from α-granules and accelerated clot lysis. The purpose of this review is to summarize current knowledge on QPD pathogenesis and the recommended approaches to QPD diagnosis and treatment.

KEYWORDS

Quebec platelet disorder - urokinase plasminogen activator - platelets - congenital platelet disorders - fibrinolysis - congenital thrombocytopenia

REFERENCES

• 1 Diamandis M, Veljkovic D K, Maurer-Spurej E, Rivard G E, Hayward C P. Quebec platelet disorder: features, pathogenesis and treatment.  Blood Coagul Fibrinolysis. 2008;  19 (2) 109-119
• 2 Veljkovic D K, Rivard G E, Diamandis M, Blavignac J, Cramer-Bordé E M, Hayward C P. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.  Blood. 2009;  113 (7) 1535-1542
• 3 Diamandis M, Paterson A D, Rommens J M et al.. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.  Blood. 2009;  113 (7) 1543-1546
• 4 Kahr W H, Zheng S, Sheth P M et al.. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.  Blood. 2001;  98 (2) 257-265
• 5 Diamandis M, Adam F, Kahr W H et al.. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis.  J Thromb Haemost. 2006;  4 (5) 1086-1094
• 6 Diamandis M, Veljkovic D K, Derome F, Rivard G E, Hayward C P. Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder.  Blood Coagul Fibrinolysis. 2008;  19 (5) 463-464
• 7 Paterson A D, Rommens J M, Bharaj B et al.. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene.  Blood. 2010;  115 (6) 1264-1266
• 8 Tracy P B, Giles A R, Mann K G, Eide L L, Hoogendoorn H, Rivard G E. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.  J Clin Invest. 1984;  74 (4) 1221-1228
• 9 Hayward C P, Rivard G E, Kane W H et al.. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect.  Blood. 1996;  87 (12) 4967-4978
• 10 Hayward C P, Cramer E M, Kane W H et al.. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules.  Blood. 1997;  89 (4) 1243-1253
• 11 Janeway C M, Rivard G E, Tracy P B, Mann K G. Factor V Quebec revisited.  Blood. 1996;  87 (9) 3571-3578
• 12 Hayward C P, Welch B, Bouchard M, Zheng S, Rivard G E. Fibrinogen degradation products in patients with the Quebec platelet disorder.  Br J Haematol. 1997;  97 (2) 497-503
• 13 McKay H, Derome F, Haq M A et al.. Bleeding risks associated with inheritance of the Quebec platelet disorder.  Blood. 2004;  104 (1) 159-165
• 14 Hayward C P, Rivard G E. Quebec platelet disorder.  Expert Rev Hematol. 2011;  4 (2) 137-141
• 15 Homo Sapiens Chromosome 10. NCBI Map Viewer Website: Homo sapiens (human) genome view Build 36 6 statistics 2009.  http://www.ncbi.nlm.nih.gov/projects/mapview/maps.cgi?taxid=9606&chr=10 Accessed October 10, 2010; 
• 16 Abbasi A H, Shaikh Q, Hussain S A. Quebec platelet disorder.  J Coll Physicians Surg Pak. 2010;  20 (8) 549-550
• 17 Sheth P M, Kahr W H, Haq M A, Veljkovic D K, Rivard G E, Hayward C P. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder.  Thromb Haemost. 2003;  90 (2) 293-298
• 18 Kufrin D, Eslin D E, Bdeir K et al.. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.  Blood. 2003;  102 (3) 926-933
• 19 Heckel J L, Sandgren E P, Degen J L, Palmiter R D, Brinster R L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator.  Cell. 1990;  62 (3) 447-456
• 20 Weiss H J, Lages B, Zheng S, Hayward C P. Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation.  Am J Hematol. 2001;  66 (2) 130-139